Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of anlotinib after first-line treatment of ovarian cancer
ChiCTR1800016907Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of anlotinib in ovarian cancer (4 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: 3-year recurrence-free survival or progression-free survival. Started Jul 2018; status: recruiting.
02
Drugs
anlotinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1800016907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016907.